Search

Your search keyword '"Kani C"' showing total 118 results
Start Over Author "Kani C"
118 results on '"Kani C"'

1. Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation

Author

Kani C., Mousavi A., Iravani M, Alimoghaddam K, Bahar B, Jahani M, and Ghavamzadeh A

Subjects
neutropenia Monotherapy Hematopoietic stem cell transplantation Randomized trial, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective: To evaluate the potential advantages of imipenem/cilastatin in control of fever in neutro-penic HSCT recipients.Patients and Method: In this single-center study, 111 consecutive febrile episodes in 104 neutropenic HSCT recipients with a mean age of 26 years were randomized to treatment either with Imipenem/cilastatin 1 g, IV, q8h or cefepime (our standard regimen) 2 g, IV, q8h. If fever persisted, se¬quential antibiotics were added in 72-hour intervals: vancomycin, amikacin and amphotericin-B. The study population was at serious risk of a poor outcome, since 73.5% of febrile episodes occurred after allogeneic and 26.5% of febrile events occurred after autologous hematopoietic stem cell transplanta¬tion."nResults: The median total duration of neutropenia was 10 days, and the median leukocyte count at study inclusion was 0.16 × 109/l. The two patient groups were comparable in terms of Age, gender, un¬derlying disease, conditioning regimen, clinical and bacterial documentation, severity and duration of neutropenia and mucositis, GI decontamination and G-CSF administration. Bacteremia was found in 20.6%, other microscopically documented infections in 9.8%, clinically documented infections in 20.6% and fever of unknown origin in 49% of the febrile episodes. Most (102) febrile episodes were evaluable for response. No significant difference was found between imipenem/cilastatin and cefepime in terms of success rate (73.1% versus 62%), empirical addition of vancomycin (38% versus 26.2%) or median duration of antibiotic therapy (7 days in both).The difference between imipenem/cilastatin and cefepime was statistically significant for median duration of fever (1.5 versus 2 days) and median time of resolution of neutropenia (12 versus 14 days). The overall response rates to initial monotherapy was significantly higher for HSCT recipients with thalassemia, MM, lymphoma, AA, than recipients with ALL, AML, CML, CLL (P

Published
2005

11. Real world, big data cost of pharmaceutical treatment for rheumatoid arthritis in Greece

Author

Souliotis, K. Golna, C. Kani, C. Nikolaidi, S. Boumpas, D.

Abstract

Introduction Rheumatoid Arthritis (RA) is a highly prevalent autoimmune disease associated with joint inflammation and destruction. Treatment for RA, especially with biologic agents (biologics), improves patient functionality and quality of life and averts costly complications or disease progression. Cost of RA pharmaceutical treatment has rarely been reported on the basis of real-world, big data. This study reports on the real-world, big data RA pharmaceutical treatment cost in Greece. Methods The Business Intelligence database of the National Organization for Healthcare Services Provision (EOPYY) was used to identify and provide analytics on patients on treatment for RA. EOPYY is responsible for funding healthcare and pharmaceutical care services for approximately 95% of the population in the country. ICD-10 codes were applied to identify patients with RA and at least one reimbursed prescription between 1 June 2014 and 31 May 2015. Results 35,873 unique patients were recorded as undergoing treatment for RA. Total reimbursed treatment cost for the study period was €81,206,363.70, of which €52,732,142.18 (64.94%) was for treatment with biologics. Of that cost, €39,724,489.71 (48.32%) accounted for treatment with anti-TNFs and/or methotrexate/corticosteroids. Conclusion Real world, big data analysis confirms that the major driver of RA pharmaceutical cost is, as expected, the cost of treatment with biologics. It is critical to be able to match this cost to the treatment outcome it produces to ensure an optimal, no-waste, evidence-based allocation of healthcare resources to need. © 2019 Souliotis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published
2019

12. Exploring knowledge and perceptions on generic drugs of final year pharmacy school students in Greece

Author

Souliotis, K. Golna, C. Kani, C. Markantonis, S.

Subjects
education, health care economics and organizations, humanities
Abstract

Objectives: The economic crisis in Greece has triggered an extensive public debate about the use of generic drugs (generics). Despite their cost-saving potential, generic market penetration remains very low. This raises questions on awareness of, perception on and preference for generics by health-care professionals and patients. This is a descriptive study on the level of knowledge and attitudes towards generics of final year pharmacy school students in Greece. Methods: An electronic questionnaire was distributed to 173 senior pharmacy school students in three Universities in Greece. Responses were submitted electronically. Results: The majority of students knew that generics contain the same active ingredient as the originator products and are cheaper. Students were somehow concerned with safety and efficacy of generics. The majority of students agreed that pharmacists should probably recommend the use of generics, and indicated that prescribing and dispensing practices would largely depend on the profit margin. Despite more than half of the students expressing a positive attitude towards generics, they were inadequately educated on their features. Conclusion: It is critical to improve knowledge of and preference for generics amongst health-care professionals from early on if to build the trust required to increase generic market penetration and achieve measurable savings in pharmaceutical expenditure. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.

Published
2019

19. Drug utilization patterns and costs of erythropoiesis-stimulating agents in an outpatient setting in Greece

Author

Papachristos, A. Kani, C. Litsa, P. Valsami, G. Souliotis, K. Saridi, M. Markantonis, S.

Subjects
hemic and lymphatic diseases
Abstract

Anemia in the elderly is often related to a higher prevalence of chronic diseases such as chronic kidney failure, arthritis, and malignancy. Erythropoiesis-stimulating agents (ESAs) have been used for years to effectively treat anemia and when used appropriately can substantially improve the health status and quality of life of older adults. Following the 2008 recession in Greece, the government introduced ESA price control restrictions, but no prescribing restrictions, in an effort to reduce drug expenditure. Objective: ESA prescribing patterns and treatment costs were analyzed to determine inappropriate or appropriate use of these agents and related health care resources in Greece. Method: A retrospective register-based drug utilization study was carried out using data from prescriptions dispensed at the public pharmacy of the largest social insurance fund (IKAETAM), for patients receiving ESAs over a six-month period. For each patient, demographic data, ESA dosage regimen, treatment indication and cost, prescriber specialty, and prescription origin were recorded. Results: A total of 14,387 prescriptions from 6,074 patients (median age 74 years) were reviewed. A substantial number of patients (13.5%) were treated for off-label indications, for which the average cost per patient per indication was higher. ESA dosage/frequency of administration varied but was in accordance with recommendations. The percentage of patients who received innovator and biosimilar erythropoietin (EPO) was 88% and 12%, respectively. Conclusion: For the optimization of ESA utilization and the reduction of treatment costs, strict ESA prescription monitoring, development of registries, and criteria for off-label indications and biosimilar use in naive patients under the umbrella of risksharing agreements should be proposed. © 2016 American Society of Consultant Pharmacists, Inc. All rights reserved.

Published
2016

22. The prevalence and treatment patterns of diabetes in the Greek population based on real-world data from the nation-wide prescription database

Author

Liatis, S. Dafoulas, G.E. Kani, C. Politi, A. Litsa, P. Sfikakis, P.P. Makrilakis, K.

Abstract

Aims Epidemiological data regarding diabetes in Greece are based on regional, small-scale studies. We aimed to identify all citizens with prescribed pharmacological treatment for diabetes, to further explore type 1 diabetes prevalence and describe pharmacological treatment patterns in type 2 diabetes. Methods The electronic prescription database of the National Organization for Health Care Services Provision was used to identify individuals who received at least two prescriptions with an ICD-10 code relevant to diabetes, dispensed between June 1st, 2014 and May 31st, 2015. Type-1 diabetes was defined in those receiving at least two fully-reimbursable insulin prescriptions with an ICD-10 code of E10 (insulin-dependent diabetes). Results The study population consisted of 10,222,779 individuals, accounting for 95% of the Greek population. Prevalence of medication-prescribed diabetes was 7.0% (720,764 individuals), ranging from 0.08% in children and adolescents, to 8.2% in adults, and 30.3% in those ⩾75 years old. Prevalence of type 1 diabetes was 0.24%, with a clear male predominance and more than half of cases developing after 14 years of age. Metformin was the most frequently prescribed medication (77.4%) in type-2 diabetes followed by DPP-4 inhibitors (44.8%) and sulphonylureas (34.5%), while insulin was used by 19.4% of patients. Conclusions This nation-wide real-world data analysis on medication-prescribed diabetes demonstrates that the current prevalence in Greece is 7.0%, with wide age variation and high figures in older adults. Identification of pharmacological patterns among patients with type 2 diabetes is a valuable guide in policy-makers’ efforts to balance a cost-effective, quality-acceptable disease management. © 2016 Elsevier Ireland Ltd

Published
2016

24. Using big data to assess prescribing patterns in Greece: The case of chronic obstructive pulmonary disease

Author

Souliotis, K. Kani, C. Papageorgiou, M. Lionis, D. Gourgoulianis, K.

Abstract

Introduction: Chronic Obstructive Pulmonary Disease (COPD) is one of the top leading causes of death and disability, and its management is focused on reducing risk factors, relieving symptoms, and preventing exacerbations. The study aim was to describe COPD prescribing patterns in Greece by using existing health administrative data for outpatients. Methods: This is a retrospective cross-sectional study based on prescriptions collected by the largest social insurance fund, during the first and last trimester of 2012. Selection criteria were the prescription of specific active substances and a COPD diagnosis. Extracted information included active substance, strength, pharmaceutical form and number of packages prescribed, diagnosis, time of dispensing, as well as insurees' age, gender, percentage of copayment and social security unique number. Statistical analysis included descriptive statistics and logistic regression. Results: 174,357 patients received medicines for COPD during the study period. Patients were almost equally distributed between male and female, and age above 55 years was strongly correlated with COPD. Most patients received a long-acting beta agonist plus inhaled corticosteroid combination (LABA +ICS), followed by long-acting muscarinic agonist (LAMA). 63% patients belonging in the 35-54 age received LABA+ICS. LAMA was prescribed more frequently among males and was strongly correlated with COPD. Conclusion: The study provides big data analysis of Greek COPD prescribing patterns. It highlights the need for appropriate COPD classification in primary care illustrating the role of electronic prescribing in ensuring appropriate prescribing. Moreover, it indicates possible gender differences in treatment response or disease severity, and the impact of statutory co-payments on prescribing. © 2016 Souliotis et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Published
2016

25. LARGE, NATION-WIDE DATA ANALYSIS-DERIVED ESTIMATED PREVALENCE OF RHEUMATOID ARTHRITIS (RA), SYSTEMIC LUPUS ERYTHEMATOSUS (SLE), AND SYSTEMIC SCLEROSIS (SSC) IN CAUCASIANS: INSIGHTS FROM THE IDENTIFICATION OF PATIENTS WITH PRESCRIBED PHARMACOLOGICAL TREATMENT AMONG 7.742.629 GREEK CITIZENS

Author

Sfikakis, P. Dafoulas, G. Boumpas, D. Drosos, A. Kitas, G. Liossis, S. N. Mannousakis, M. Sidiropoulos, P. and Sakkas, L. Tzioufas, A. Vassilopoulos, D. and Vlachoyiannopoulos, P. Kani, C. Paterakis, P. Litsa, P.

Published
2015

30. Health Expenditure By Disease Age And Gender In Greece

Author

Siskou, O, primary, Schneider, M, additional, Craig, M, additional, Kaitelidou, D, additional, Priftis, C, additional, Kani, C, additional, Litsa, P, additional, Galanis, P, additional, Lemonidou, C, additional, Vafeiadis, J, additional, and Liaropoulos, L, additional

Published
2016
Full Text
View/download PDF

33. SAT0361 Large, Nation-Wide Data Analysis-Derived Estimated Prevalence of Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), and Systemic Sclerosis (SSC) in Caucasians: Insights from the Identification of Patients with Prescribed Pharmacological Treatment Among 7.742.629 Greek Citizens

Author

Sfikakis, P., primary, Dafoulas, G., additional, Boumpas, D., additional, Drosos, A., additional, Kitas, G., additional, Liossis, S.N., additional, Mannousakis, M., additional, Sidiropoulos, P., additional, Sakkas, L., additional, Tzioufas, A., additional, Vassilopoulos, D., additional, Vlachoyiannopoulos, P., additional, Kani, C., additional, Paterakis, P., additional, and Litsa, P., additional

Published
2015
Full Text
View/download PDF

35. Monitoring of subcutaneous dalteparin in patients with renat insufficiency under intensive care: an observational study

Author

Kani, C Markantonis, SL Nicolaou, C Maggina, N

Abstract

Objective: The objective of this study was to investigate the pharmacodynamic parameters of dalteparin in patients with renal insufficiency under intensive care. Materials and Methods: In this open, nonrandomized, nonblinded, prospective, single-dose observational study, 10 critically ill patients with renal insufficiency (mean creatinine clearance 29.5 +/- 6.42 mL/mm) were administered a single 5000-IU Subcutaneous dose of dalteparin. Results: Dalteparin blood levels were estimated indirectly over a 12-hour period by measuring anti-Xa activity and by performing a clotting assay known as the ATHU (AHEPA Thrombosis and Hemostasis Unit) test. Maximum anti-Xa activity (ie, 0.42 +/- 0.13 IU/mL) was achieved 4 hours after administration (in 8 of 10 patients). Adequate anticoagulant activity was maintained throughout the 12-hour dosage interval in all study patients. However, at time 0 hour of the study, 36 hours after the administration of a previous dose of dalteparin, considerable anti-Xa activity (ie, 0.39 +/- 0.11 IU/mL) was measured in 6 patients. A good correlation was found between anti-Xa activity and the results of the ATHU test. Conclusions: The presence of medium/severe edema and the concurrent administration of 1 to 3 inotropic drugs appear to contribute to a decrease in the rate of elimination of dalteparin, resulting in a greater-than-expected (as a result of decreased renal function) prolongation of its pharmacologic activity. We recommend that care be taken with repeated dosing of dalteparin in intensive care unit patients taking inotropic drugs until observed results can be confirmed. (c) 2006 Elsevier Inc. All rights reserved.

Published
2006

44. Embryology

Author

Gandhi, G., primary, Allahbadia, G., additional, Kagalwala, S., additional, Allahbadia, A., additional, Ramesh, S., additional, Patel, K., additional, Hinduja, R., additional, Chipkar, V., additional, Madne, M., additional, Ramani, R., additional, Joo, J. K., additional, Jeung, J. E., additional, Go, K. R., additional, Lee, K. S., additional, Goto, H., additional, Hashimoto, S., additional, Amo, A., additional, Yamochi, T., additional, Iwata, H., additional, Morimoto, Y., additional, Koifman, M., additional, Lahav-Baratz, S., additional, Blais, E., additional, Megnazi-Wiener, Z., additional, Ishai, D., additional, Auslender, R., additional, Dirnfeld, M., additional, Zaletova, V., additional, Zakharova, E., additional, Krivokharchenko, I., additional, Zaletov, S., additional, Zhu, L., additional, Li, Y., additional, Zhang, H., additional, Ai, J., additional, Jin, L., additional, Zhang, X., additional, Rajan, N., additional, Kovacs, A., additional, Foley, C., additional, Flanagan, J., additional, O'Callaghan, J., additional, Waterstone, J., additional, Dineen, T., additional, Dahdouh, E. M., additional, St-Michel, P., additional, Granger, L., additional, Carranza-Mamane, B., additional, Faruqi, F., additional, Kattygnarath, T. V., additional, Gomes, F. L. A. F., additional, Christoforidis, N., additional, Ioakimidou, C., additional, Papas, C., additional, Moisidou, M., additional, Chatziparasidou, A., additional, Klaver, M., additional, Tilleman, K., additional, De Sutter, P., additional, Lammers, J., additional, Freour, T., additional, Splingart, C., additional, Barriere, P., additional, Ikeno, T., additional, Nakajyo, Y., additional, Sato, Y., additional, Hirata, K., additional, Kyoya, T., additional, Kyono, K., additional, Campos, F. B., additional, Meseguer, M., additional, Nogales, M., additional, Martinez, E., additional, Ariza, M., additional, Agudo, D., additional, Rodrigo, L., additional, Garcia-Velasco, J. A., additional, Lopes, A. S., additional, Frederickx, V., additional, Vankerkhoven, G., additional, Serneels, A., additional, Roziers, P., additional, Puttermans, P., additional, Campo, R., additional, Gordts, S., additional, Fragouli, E., additional, Alfarawati, S., additional, Spath, K., additional, Wells, D., additional, Liss, J., additional, Lukaszuk, K., additional, Glowacka, J., additional, Bruszczynska, A., additional, Gallego, S. C., additional, Lopez, L. O., additional, Vila, E. O., additional, Garcia, M. G., additional, Canas, C. L., additional, Segovia, A. G., additional, Ponce, A. G., additional, Calonge, R. N., additional, Peregrin, P. C., additional, Ito, K., additional, Nakaoka, Y., additional, Alcoba, D. D., additional, Valerio, E. G., additional, Conzatti, M., additional, Tornquist, J., additional, Kussler, A. P., additional, Pimentel, A. M., additional, Corleta, H. E., additional, Brum, I. S., additional, Boyer, P., additional, Montjean, D., additional, Tourame, P., additional, Gervoise-Boyer, M., additional, Cohen, J., additional, Lefevre, B., additional, Radio, C. I., additional, Wolf, J. P., additional, Ziyyat, A., additional, De Croo, I., additional, Tolpe, A., additional, Degheselle, S., additional, Van de Velde, A., additional, Van den Abbeel, E., additional, Gandhi, G., additional, Kuwayama, M., additional, Khatoon, A., additional, Alsule, S., additional, Inaba, M., additional, Ohgaki, A., additional, Ohtani, A., additional, Matsumoto, H., additional, Mizuno, S., additional, Mori, R., additional, Fukuda, A., additional, Umekawa, Y., additional, Yoshida, A., additional, Tanigiwa, S., additional, Seida, K., additional, Suzuki, H., additional, Tanaka, M., additional, Vahabi, Z., additional, Yazdi, P. E., additional, Dalman, A., additional, Ebrahimi, B., additional, Mostafaei, F., additional, Niknam, M. R., additional, Watanabe, S., additional, Kamihata, M., additional, Tanaka, T., additional, Matsunaga, R., additional, Yamanaka, N., additional, Kani, C., additional, Ishikawa, T., additional, Wada, T., additional, Morita, H., additional, Miyamura, H., additional, Nishio, E., additional, Ito, M., additional, Kuwahata, A., additional, Ochi, M., additional, Horiuchi, T., additional, Dal Canto, M., additional, Guglielmo, M. C., additional, Fadini, R., additional, Renzini, M. M., additional, Albertini, D. F., additional, Novara, P., additional, Lain, M., additional, Brambillasca, F., additional, Turchi, D., additional, Sottocornola, M., additional, Coticchio, G., additional, Kato, M., additional, Fukunaga, N., additional, Nagai, R., additional, Kitasaka, H., additional, Yoshimura, T., additional, Tamura, F., additional, Hasegawa, N., additional, Nakayama, K., additional, Takeuchi, M., additional, Ohno, H., additional, Aoyagi, N., additional, Kojima, E., additional, Itoi, F., additional, Hashiba, Y., additional, Asada, Y., additional, Kikuchi, H., additional, Iwasa, Y., additional, Kamono, T., additional, Suzuki, A., additional, Yamada, K., additional, Kanno, H., additional, Sasaki, K., additional, Murakawa, H., additional, Matsubara, M., additional, Yoshida, H., additional, Valdespin, C., additional, Elhelaly, M., additional, Chen, P., additional, Pangestu, M., additional, Catt, S., additional, Hojnik, N., additional, Kovacic, B., additional, Roglic, P., additional, Taborin, M., additional, Zafosnik, M., additional, Knez, J., additional, Vlaisavljevic, V., additional, Mori, C., additional, Yabuuchi, A., additional, Ezoe, K., additional, Takayama, Y., additional, Aono, F., additional, Kato, K., additional, Radwan, P., additional, Krasinski, R., additional, Chorobik, K., additional, Radwan, M., additional, Stoppa, M., additional, Maggiulli, R., additional, Capalbo, A., additional, Ievoli, E., additional, Dovere, L., additional, Scarica, C., additional, Albricci, L., additional, Romano, S., additional, Sanges, F., additional, Barnocchi, N., additional, Papini, L., additional, Vivarelli, A., additional, Ubaldi, F. M., additional, Rienzi, L., additional, Bono, S., additional, Spizzichino, L., additional, Rubio, C., additional, Fiorentino, F., additional, Ferris, J., additional, Favetta, L. A., additional, MacLusky, N., additional, King, W. A., additional, Madani, T., additional, Jahangiri, N., additional, Aflatoonian, R., additional, Cater, E., additional, Hulme, D., additional, Berrisford, K., additional, Jenner, L., additional, Campbell, A., additional, Fishel, S., additional, Zhang, X. Y., additional, Yilmaz, A., additional, Hananel, H., additional, Ao, A., additional, Vutyavanich, T., additional, Piromlertamorn, W., additional, Saenganan, U., additional, Samchimchom, S., additional, Wirleitner, B., additional, Lejeune, B., additional, Zech, N. H., additional, Vanderzwalmen, P., additional, Albani, E., additional, Parini, V., additional, Smeraldi, A., additional, Menduni, F., additional, Antonacci, R., additional, Marras, A., additional, Levi, S., additional, Morreale, G., additional, Pisano, B., additional, Di Biase, A., additional, Di Rosa, A., additional, Setti, P. E. L., additional, Puard, V., additional, Cadoret, V., additional, Tranchant, T., additional, Gauthier, C., additional, Reiter, E., additional, Guerif, F., additional, Royere, D., additional, Yoon, S. Y., additional, Eum, J. H., additional, Park, E. A., additional, Kim, T. Y., additional, Yoon, T. K., additional, Lee, D. R., additional, Lee, W. S., additional, Cabal, A. C., additional, Vallejo, B., additional, Campos, P., additional, Sanchez, E., additional, Serrano, J., additional, Remohi, J., additional, Nagornyy, V., additional, Mazur, P., additional, Mykytenko, D., additional, Semeniuk, L., additional, Zukin, V., additional, Guilherme, P., additional, Madaschi, C., additional, Bonetti, T. C. S., additional, Fassolas, G., additional, Izzo, C. R., additional, Santos, M. J. D. L., additional, Beltran, D., additional, Garcia-Laez, V., additional, Escriba, M. J., additional, Grau, N., additional, Escrich, L., additional, Albert, C., additional, Zuzuarregui, J. L., additional, Pellicer, A., additional, LU, Y., additional, Nikiforaki, D., additional, Meerschaut, F. V., additional, Neupane, J., additional, De Vos, W. H., additional, Lierman, S., additional, Deroo, T., additional, Heindryckx, B., additional, Li, J., additional, Chen, X. Y., additional, Lin, G., additional, Huang, G. N., additional, Sun, Z. Y., additional, Zhong, Y., additional, Zhang, B., additional, Li, T., additional, Zhang, S. P., additional, Ye, H., additional, Han, S. B., additional, Liu, S. Y., additional, Zhou, J., additional, Lu, G. X., additional, Zhuang, G. L., additional, Muela, L., additional, Roldan, M., additional, Gadea, B., additional, Martinez, M., additional, Perez, I., additional, Munoz, M., additional, Castello, C., additional, Asensio, M., additional, Fernandez, P., additional, Farreras, A., additional, Rovira, S., additional, Capdevila, J. M., additional, Velilla, E., additional, Lopez-Teijon, M., additional, Kovacs, P., additional, Matyas, S. Z., additional, Forgacs, V., additional, Reichart, A., additional, Rarosi, F., additional, Bernard, A., additional, Torok, A., additional, Kaali, S. G., additional, Sajgo, A., additional, Pribenszky, C. S., additional, Sozen, B., additional, Ozturk, S., additional, Yaba-Ucar, A., additional, Demir, N., additional, Gelo, N., additional, Stanic, P., additional, Hlavati, V., additional, ogoric, S., additional, Pavicic-Baldani, D., additional, prem-Goldtajn, M., additional, Radakovic, B., additional, Kasum, M., additional, Strelec, M., additional, Canic, T., additional, imunic, V., additional, Vrcic, H., additional, Ajina, M., additional, Negra, D., additional, Ben-Ali, H., additional, Jallad, S., additional, Zidi, I., additional, Meddeb, S., additional, Bibi, M., additional, Khairi, H., additional, Saad, A., additional, Gamiz, P., additional, Viloria, T., additional, Lima, E. T., additional, Fernandez, M. P., additional, Prieto, J. A. A., additional, Varela, M. O., additional, Kassa, D., additional, Munoz, E. M., additional, Kani, K., additional, Nor-Ashikin, M. N. K., additional, Norhazlin, J. M. Y., additional, Norita, S., additional, Wan-Hafizah, W. J., additional, Mohd-Fazirul, M., additional, Razif, D., additional, Hoh, B. P., additional, Dale, S., additional, Woodhead, G., additional, Andronikou, S., additional, Francis, G., additional, Tailor, S., additional, Vourliotis, M., additional, Almeida, P. A., additional, Krivega, M., additional, Van de Velde, H., additional, Lee, R. K., additional, Hwu, Y. M., additional, Lu, C. H., additional, Li, S. H., additional, Vaiarelli, A., additional, Desgro, M., additional, Baggiani, A., additional, Zannoni, E., additional, Kermavner, L. B., additional, Klun, I. V., additional, Pinter, B., additional, Vrtacnik-Bokal, E., additional, De Paepe, C., additional, Cauffman, G., additional, Verheyen, G., additional, Stoop, D., additional, Liebaers, I., additional, Stecher, A., additional, Zintz, M., additional, Neyer, A., additional, Bach, M., additional, Baramsai, B., additional, Schwerda, D., additional, Wiener-Megnazi, Z., additional, Fridman, M., additional, Blais, I., additional, Akerud, H., additional, Lindgren, K., additional, Karehed, K., additional, Wanggren, K., additional, Hreinsson, J., additional, Freijomil, B., additional, Weiss, A., additional, Neril, R., additional, Geslevich, J., additional, Beck-Fruchter, R., additional, Lavee, M., additional, Golan, J., additional, Ermoshkin, A., additional, Shalev, E., additional, Shi, W., additional, Zhang, S., additional, Zhao, W., additional, Xue, X. I. A., additional, Wang, M. I. N., additional, Bai, H., additional, Shi, J., additional, Smith, H. L., additional, Shaw, L., additional, Kimber, S., additional, Brison, D., additional, Boumela, I., additional, Assou, S., additional, Haouzi, D., additional, Ahmed, O. A., additional, Dechaud, H., additional, Hamamah, S., additional, Dasiman, R., additional, Nor-Shahida, A. R., additional, Salina, O., additional, Gabriele, R. A. F., additional, Ben-Yosef, D., additional, Shwartz, T., additional, Cohen, T., additional, Carmon, A., additional, Raz, N. M., additional, Malcov, M., additional, Frumkin, T., additional, Almog, B., additional, Vagman, I., additional, Kapustiansky, R., additional, Reches, A., additional, Azem, F., additional, Amit, A., additional, Cetinkaya, M., additional, Pirkevi, C., additional, Yelke, H., additional, Kumtepe, Y., additional, Atayurt, Z., additional, Kahraman, S., additional, Risco, R., additional, Hebles, M., additional, Saa, A. M., additional, Vilches-Ferron, M. A., additional, Sanchez-Martin, P., additional, Lucena, E., additional, Lucena, M., additional, Heras, M. D. L., additional, Agirregoikoa, J. A., additional, Barrenetxea, G., additional, De Pablo, J. L., additional, Lehner, A., additional, Pribenszky, C., additional, Murber, A., additional, Rigo, J., additional, Urbancsek, J., additional, Fancsovits, P., additional, Bano, D. G., additional, Sanchez-Leon, A., additional, Marcos, J., additional, Molla, M., additional, Amorocho, B., additional, Nicolas, M., additional, Fernandez, L., additional, Landeras, J., additional, Adeniyi, O. A., additional, Ehbish, S. M., additional, Brison, D. R., additional, Egashira, A., additional, Murakami, M., additional, Nagafuchi, E., additional, Tanaka, K., additional, Tomohara, A., additional, Mine, C., additional, Otsubo, H., additional, Nakashima, A., additional, Otsuka, M., additional, Yoshioka, N., additional, Kuramoto, T., additional, Choi, D., additional, Yang, H., additional, Park, J. H., additional, Jung, J. H., additional, Hwang, H. G., additional, Lee, J. H., additional, Lee, J. E., additional, Kang, A. S., additional, Yoo, J. H., additional, Kwon, H. C., additional, Lee, S. J., additional, Bang, S., additional, Shin, H., additional, Lim, H. J., additional, Min, S. H., additional, Yeon, J. Y., additional, Koo, D. B., additional, Higo, S., additional, Ruvalcaba, L., additional, Kobayashi, M., additional, Takeuchi, T., additional, Miwa, A., additional, Nagai, Y., additional, Momma, Y., additional, Takahashi, K., additional, Chuko, M., additional, Nagai, A., additional, Otsuki, J., additional, Kim, S. G., additional, Kim, Y. Y., additional, Kim, H. J., additional, Park, I. H., additional, Sun, H. G., additional, Lee, K. H., additional, Song, H. J., additional, Costa-Borges, N., additional, Belles, M., additional, Herreros, J., additional, Teruel, J., additional, Ballesteros, A., additional, Calderon, G., additional, Vossaert, L., additional, Qian, C., additional, Lu, Y., additional, Parys, J. B., additional, Deforce, D., additional, Leybaert, L., additional, Surlan, L., additional, Otasevic, V., additional, Velickovic, K., additional, Golic, I., additional, Vucetic, M., additional, Stankovic, V., additional, Stojnic, J., additional, Radunovic, N., additional, Tulic, I., additional, Korac, B., additional, Korac, A., additional, Elias, R., additional, Neri, Q. V., additional, Fields, T., additional, Schlegel, P. N., additional, Rosenwaks, Z., additional, Palermo, G. D., additional, Gilson, A., additional, Piront, N., additional, Heens, B., additional, Vastersaegher, C., additional, Vansteenbrugge, A., additional, Pauwels, P. C. P., additional, Abdel-Raheem, M. F., additional, Abdel-Rahman, M. Y., additional, Abdel-Gaffar, H. M., additional, Sabry, M., additional, Kasem, H., additional, Rasheed, S. M., additional, Amin, M., additional, Abdelmonem, A., additional, Ait-Allah, A. S., additional, VerMilyea, M., additional, Anthony, J., additional, Bucci, J., additional, Croly, S., additional, Coutifaris, C., additional, Cimadomo, D., additional, Dusi, L., additional, Colamaria, S., additional, Baroni, E., additional, Giuliani, M., additional, Sapienza, F., additional, Buffo, L., additional, Zivi, E., additional, Aizenman, E., additional, Barash, D., additional, Gibson, D., additional, Shufaro, Y., additional, Perez, M., additional, Aguilar, J., additional, Taboas, E., additional, Ojeda, M., additional, Suarez, L., additional, Munoz, E., additional, Casciani, V., additional, Minasi, M. G., additional, Scarselli, F., additional, Terribile, M., additional, Zavaglia, D., additional, Colasante, A., additional, Franco, G., additional, Greco, E., additional, Hickman, C., additional, Cook, C., additional, Gwinnett, D., additional, Trew, G., additional, Carby, A., additional, Lavery, S., additional, Asgari, L., additional, Paouneskou, D., additional, Jayaprakasan, K., additional, Maalouf, W., additional, Campbell, B. K., additional, Rega, E., additional, Alteri, A., additional, Cotarelo, R. P., additional, Rubino, P., additional, Colicchia, A., additional, Giannini, P., additional, Devjak, R., additional, Papler, T. B., additional, Tacer, K. F., additional, Verdenik, I., additional, Iussig, B., additional, Gala, A., additional, Ferrieres, A., additional, Vincens, C., additional, Bringer-Deutsch, S., additional, Brunet, C., additional, Conaghan, J., additional, Tan, L., additional, Gvakharia, M., additional, Ivani, K., additional, Chen, A., additional, Pera, R. R., additional, Bowman, N., additional, Montgomery, S., additional, Best, L., additional, Duffy, S., additional, Hirata, R., additional, Aoi, Y., additional, Habara, T., additional, Hayashi, N., additional, Dinopoulou, V., additional, Partsinevelos, G. A., additional, Bletsa, R., additional, Mavrogianni, D., additional, Anagnostou, E., additional, Stefanidis, K., additional, Drakakis, P., additional, Loutradis, D., additional, Hernandez, J., additional, Leon, C. L., additional, Puopolo, M., additional, Palumbo, A., additional, Atig, F., additional, Kerkeni, A., additional, D'Ommar, G., additional, Herrera, A. K., additional, Lozano, L., additional, Majerfeld, M., additional, Ye, Z., additional, Zaninovic, N., additional, Clarke, R., additional, Bodine, R., additional, Nagorny, V., additional, Zabala, A., additional, Pessino, T., additional, Outeda, S., additional, Blanco, L., additional, Leocata, F., additional, Asch, R., additional, Rajikin, M. H., additional, Nuraliza, A. S., additional, Machac, S., additional, Hubinka, V., additional, Larman, M., additional, Koudelka, M., additional, Budak, T. P., additional, Membrado, O. O., additional, Martinez, E. S., additional, Wilson, P., additional, McClure, A., additional, Nargund, G., additional, Raso, D., additional, Insua, M. F., additional, Lotti, B., additional, Giordana, S., additional, Baldi, C., additional, Barattini, J., additional, Cogorno, M., additional, Peri, N. F., additional, Neuspiller, F., additional, Resta, S., additional, Filannino, A., additional, Maggi, E., additional, Cafueri, G., additional, Ferraretti, A. P., additional, Magli, M. C., additional, Gianaroli, L., additional, Sioga, A., additional, Oikonomou, Z., additional, Chatzimeletiou, K., additional, Oikonomou, L., additional, Kolibianakis, E., additional, Tarlatzis, B. C., additional, Sarkar, M. R., additional, Ray, D., additional, Bhattacharya, J., additional, Alises, J. M., additional, Gumbao, D., additional, Hickman, C. F. L., additional, Fiorentino, I., additional, Gualtieri, R., additional, Barbato, V., additional, Braun, S., additional, Mollo, V., additional, Netti, P., additional, Talevi, R., additional, Bayram, A., additional, Findikli, N., additional, Serdarogullari, M., additional, Sahin, O., additional, Ulug, U., additional, Tosun, S. B., additional, Bahceci, M., additional, Leon, A. S., additional, Cardoso, M. C. A., additional, Aguiar, A. P. S., additional, Sartorio, C., additional, Evangelista, A., additional, Gallo-Sa, P., additional, Erthal-Martins, M. C., additional, Mantikou, E., additional, Jonker, M. J., additional, de Jong, M., additional, Wong, K. M., additional, van Montfoort, A. P. A., additional, Breit, T. M., additional, Repping, S., additional, Mastenbroek, S., additional, Power, E., additional, Jordan, K., additional, Aksoy, T., additional, Gultomruk, M., additional, Aktan, A., additional, Goktas, C., additional, Petracco, R., additional, Okada, L., additional, Azambuja, R., additional, Badalotti, F., additional, Michelon, J., additional, Reig, V., additional, Kvitko, D., additional, Tagliani-Ribeiro, A., additional, Badalotti, M., additional, Petracco, A., additional, Aydin, B., additional, Cepni, I., additional, Rodriguez-Arnedo, D., additional, Ten, J., additional, Guerrero, J., additional, Ochando, I., additional, and Bernabeu, R., additional

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results